BriaCell Therapeutics Corp. (BCTX) vs Elutia Inc (ELUT)
A side-by-side comparison of BriaCell Therapeutics Corp. and Elutia Inc across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BCTX
BriaCell Therapeutics Corp.
$4.02HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
ELUT
Elutia Inc
$0.78HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — BCTX vs ELUT
growth of $100 · dividends reinvested · last 6yBCTX -99.4% (-56.8%/yr)ELUT -94.3% (-38.0%/yr)ELUT compounded faster over this window
Log scale — wide-divergence pair
BCTX ELUT
BCTX vs ELUT: by the numbers
- •BCTX is the larger company ($35M vs $34M market cap).
- •ELUT is profitable (426.93% net margin) while BCTX runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | BCTX | ELUT |
|---|---|---|
| P/E ratio | N/A | 0.83 |
| P/S ratio | N/A | 2.83 |
| P/B ratio | 1.45 | 2.18 |
Profitability
| Metric | BCTX | ELUT |
|---|---|---|
| Gross margin | 0.00% | 57.82% |
| Operating margin | 0.00% | -149.78% |
| Net margin | 0.00% | 426.93% |
| ROE | -154.06% | 329.02% |
| ROIC | -164.58% | -79.27% |
Growth (annualized)
| Metric | BCTX | ELUT |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -22.04% |
| Total return CAGR (5Y) | -67.32% | -33.96% |
Frequently asked
- Is BCTX or ELUT more profitable?
- ELUT runs the higher net margin — BCTX at 0.00% versus ELUT at 426.93%.
- How have BCTX and ELUT total returns compared?
- Over the past 5 years, BCTX delivered -67.32% and ELUT delivered -33.96% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Elutia P/E ratioBriaCell Therapeutics ROEElutia ROEBriaCell Therapeutics operating marginElutia operating marginBriaCell Therapeutics revenue growthElutia revenue growthBriaCell Therapeutics free cash flowElutia free cash flow
BriaCell Therapeutics & Elutia appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.